Troost Els, Meyns Bart, Daenen Willem, Van de Werf Frans, Gewillig Marc, Van Deyk Kristien, Moons Philip, Budts Werner
Department of Cardiology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Eur Heart J. 2007 Oct;28(20):2503-9. doi: 10.1093/eurheartj/ehm376. Epub 2007 Sep 19.
Homografts are frequently implanted in patients with tetralogy of Fallot (TOF). However, the lifespan of homografts is shorter than that of graft recipients, thus making surgical re-intervention unavoidable. Therefore, to determine variables that could influence their survival, we retrospectively studied the survival pattern of homografts used to treat TOF.
Sixty-eight TOF patients, >14 years of age (mean age: 34 +/- 11; 71% male), were selected from our database of congenital cardiology cases. These patients underwent their first homograft implantation at a median age of 24 years (range: 14-49). The primary endpoint, homograft failure, was defined as homograft replacement or percutaneous balloon dilatation when the echocardiographic gradient reached more than 50 mmHg. Kaplan-Meier analysis revealed that the mean event-free survival time of first homografts was 14.6 years (CI, 12.9-16.2 years). The median increase in the homograft gradient was 1.1 mmHg/year (range: 0.0-22.1) for a median follow-up time of 8.4 years (range: 1.3-17.9). Stepwise regression analysis identified the homograft gradient at 1 month after surgery to be prognostic for homograft degeneration (R(2) = 0.23, beta = 0.26, P = 0.001). Immunological variables, gender, and post-operative inflammatory indicators were unrelated to the degree of homograft gradient increase. Finally, patient age at the time of first homograft implantation and previous palliative surgery was significantly associated with the gradient at 1 month (Spearman's rho = -0.41 and -0.29, respectively; P = 0.004 and 0.048, respectively).
Homograft survival in patients with TOF repair is quite good. However, some patients develop accelerated homograft degeneration. We found that the gradient of the homograft 1 month after surgery is most indicative of accelerated homograft degeneration. We hypothesize that mechanical, not immunological, factors play an important role in homograft degeneration.
同种异体移植物常用于法洛四联症(TOF)患者。然而,同种异体移植物的使用寿命短于接受移植者,因此手术再次干预不可避免。因此,为了确定可能影响其存活的变量,我们回顾性研究了用于治疗TOF的同种异体移植物的存活模式。
从我们的先天性心脏病病例数据库中选取68例年龄大于14岁(平均年龄:34±11岁;71%为男性)的TOF患者。这些患者首次同种异体移植的中位年龄为24岁(范围:14 - 49岁)。主要终点,同种异体移植物失败,定义为当超声心动图压差超过50 mmHg时进行同种异体移植物置换或经皮球囊扩张。Kaplan - Meier分析显示首次同种异体移植物的平均无事件存活时间为14.